106 related articles for article (PubMed ID: 18024388)
1. Interferon alpha induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation.
Helbig G; Stella-Holowiecka B; Majewski M; Lewandowska M; Holowiecki J
Haematologica; 2007 Nov; 92(11):e118-9. PubMed ID: 18024388
[TBL] [Abstract][Full Text] [Related]
2. Screening for JAK2 V617F point mutation in patients with hypereosinophilic syndrome-in response to 'Hypereosinophilic syndrome: another face of janus?' by Dahabreh et al. published in Leukemia Research, in press.
Helbig G; Majewski M; Wieczorkiewicz A; Bober G; Grzegorczyk J; Dziaczkowska-Suszek J; Soja A; Bartkowska-Chrobok A; Krawczyk M; Krzemień S
Leuk Res; 2009 Mar; 33(3):e1-2. PubMed ID: 18466967
[No Abstract] [Full Text] [Related]
3. AlphaIFN-induced hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(1;5).
Luciano L; Catalano L; Sarrantonio C; Guerriero A; Califano C; Rotoli B
Haematologica; 1999 Jul; 84(7):651-3. PubMed ID: 10406909
[TBL] [Abstract][Full Text] [Related]
4. Presence of the JAK2 V617F mutation in a patient with chronic neutrophilic leukemia and effective response to interferon α-2b.
Zhang X; Pan J; Guo J
Acta Haematol; 2013; 130(1):44-6. PubMed ID: 23391844
[TBL] [Abstract][Full Text] [Related]
5. Hypereosinophilic syndrome: another face of janus?
Dahabreh IJ; Giannouli S; Zoi C; Zoi K; Loukopoulos D; Voulgarelis M
Leuk Res; 2008 Sep; 32(9):1483-5. PubMed ID: 18243306
[No Abstract] [Full Text] [Related]
6. [Studying of clinical and laboratory features of chronic eosinophilic leukemias /hypereosinophilic syndrome].
Zhang Y; Yu MH; Xu SC; Yang L; Yu Y; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):3-8. PubMed ID: 18512307
[TBL] [Abstract][Full Text] [Related]
7. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
[TBL] [Abstract][Full Text] [Related]
8. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
9. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.
Kiladjian JJ; Cassinat B; Chevret S; Turlure P; Cambier N; Roussel M; Bellucci S; Grandchamp B; Chomienne C; Fenaux P
Blood; 2008 Oct; 112(8):3065-72. PubMed ID: 18650451
[TBL] [Abstract][Full Text] [Related]
10. Chronic Eosinophilic Leukaemia Associated with JAK2 Exon 13 Insertion/Deletion Mutations.
Lafferty N; Salmon M; Cross NCP; Singer I; Cooney A; Jayaprakash R
Acta Haematol; 2022; 145(2):201-206. PubMed ID: 34515041
[TBL] [Abstract][Full Text] [Related]
11. Clinical and cytogenetic remission induced by interferon-alpha in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation.
Yamada O; Kitahara K; Imamura K; Ozasa H; Okada M; Mizoguchi H
Am J Hematol; 1998 Jun; 58(2):137-41. PubMed ID: 9625582
[TBL] [Abstract][Full Text] [Related]
12. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.
Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P
Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504
[TBL] [Abstract][Full Text] [Related]
14. Severe asthma with blood hypereosinophilia associated with
Tabèze L; Marchand-Adam S; Borie R; Justet A; Dupin C; Dombret MC; Crestani B; Taillé C
Eur Respir J; 2019 Jun; 53(6):. PubMed ID: 31000675
[No Abstract] [Full Text] [Related]
15. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia.
Lierman E; Selleslag D; Smits S; Billiet J; Vandenberghe P
Blood; 2012 Aug; 120(7):1529-31. PubMed ID: 22899477
[No Abstract] [Full Text] [Related]
17. FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.
Cools J
Verh K Acad Geneeskd Belg; 2005; 67(3):169-76. PubMed ID: 16089297
[TBL] [Abstract][Full Text] [Related]
18. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
19. Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells.
Kiladjian JJ; Massé A; Cassinat B; Mokrani H; Teyssandier I; le Couédic JP; Cambier N; Almire C; Pronier E; Casadevall N; Vainchenker W; Chomienne C; Delhommeau F;
Leukemia; 2010 Aug; 24(8):1519-23. PubMed ID: 20520643
[No Abstract] [Full Text] [Related]
20. Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3-PDGFRB fusion.
Li Z; Yang R; Zhao J; Yuan R; Lu Q; Li Q; Tse W
Pediatr Blood Cancer; 2011 Mar; 56(3):463-6. PubMed ID: 21072821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
